Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA). The RENASYS TOUCH NPWT System demonstrated clinical efficacy,1,2,3,4 and operational fitness including portability,2 an intuitive interface,5,6,7 and the ability to provide a range of therapy modes, ...

Core Insights - Smith+Nephew has been awarded a 10-year contract worth up to $75 million by the U.S. Department of Defense to provide its RENASYS TOUCH Negative Pressure Wound Therapy Systems [1][8] - The RENASYS TOUCH NPWT System is designed for clinical efficacy and operational fitness, including portability and an intuitive interface, allowing for individualized patient care [2][5] - The system will support military medical providers in various care settings, including prolonged casualty care and aeromedical transport [2][5] Group 1 - The RENASYS TOUCH NPWT System is manufactured in the United States, emphasizing local production [2] - The system is intended to simplify negative pressure wound therapy for military applications, addressing the complexities of future conflicts [5] - Smith+Nephew has a historical commitment to military medical needs, dating back to World War I, and continues to innovate in wound care [6][10] Group 2 - In 2024, Smith+Nephew entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to enhance wound and burn care in military settings [6] - The company generated annual sales of $5.8 billion in 2024 and operates in around 100 countries, indicating a strong global presence [11]